10K views · 197 reactions | Radical surgery, the standard of care in muscle-invasive urothelial carcinoma, is performed with curative intent, but more than 50% of patients have lethal metastatic recurrence. Adjuvant chemotherapy may prolong disease-free survival, but no consensus regarding routine therapy has emerged. New research findings are summarized in a short video. https://nej.md/2Rc0JTv | The New England Journal of Medicine | Facebook

15K views · 269 reactions | Combination platinum-based chemotherapy is the standard first-line treatment for advanced urothelial carcinoma, but most patients have disease progression within 9 months; the median overall survival is 14 to 15 months with cisplatin-based regimens and 9 to 10 months with carboplatin-based regimens. New research findings are summarized in a short video. https://nej.md/35OBRpy | The New England Journal of Medicine | Facebook